G

Genematrix Inc
KOSDAQ:109820

Watchlist Manager
Genematrix Inc
KOSDAQ:109820
Watchlist
Price: 2 340 KRW 3.08% Market Closed
Market Cap: ₩47.7B

Operating Margin

-9.2%
Current
Improving
by 13.6%
vs 3-y average of -22.8%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-9.2%
=
Operating Income
₩-961.3m
/
Revenue
₩10.4B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-9.2%
=
Operating Income
₩-961.3m
/
Revenue
₩10.4B

Peer Comparison

Country Company Market Cap Operating
Margin
KR
Genematrix Inc
KOSDAQ:109820
46.7B KRW
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 80% of companies in Korea
Percentile
20th
Based on 2 615 companies
20th percentile
-9.2%
Low
-163 055.6% — -2.2%
Typical Range
-2.2% — 6.8%
High
6.8% — 22 874.8%
Distribution Statistics
Korea
Min -163 055.6%
30th Percentile -2.2%
Median 2.7%
70th Percentile 6.8%
Max 22 874.8%

Genematrix Inc
Glance View

Market Cap
47.7B KRW
Industry
Biotechnology

GENEMATRIX, Inc. engages in the development of platform and molecular diagnostics products. The company is headquartered in Seongnam, Gyeonggi-Do and currently employs 60 full-time employees. The company went IPO on 2009-11-06. The firm operates in two segments: pharmaceutical development and diagnostic medicine. Its pharmaceutical development segment specializes in the development of restriction fragment mass polymorphism (RFMP) genotyping technology for diagnosis of hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV) and others. Its diagnostic medicine segment specializes in the manufacture and sale of liver-function examination reagents, and import and sale of medical equipment and reagents.

Genematrix Inc Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-9.2%
=
Operating Income
₩-961.3m
/
Revenue
₩10.4B
What is Genematrix Inc's current Operating Margin?

The current Operating Margin for Genematrix Inc is -9.2%, which is above its 3-year median of -22.8%.

How has Operating Margin changed over time?

Over the last 3 years, Genematrix Inc’s Operating Margin has decreased from -5.2% to -9.2%. During this period, it reached a low of -41% on Jun 30, 2023 and a high of -5.2% on May 30, 2022.

Back to Top